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ringdue tomutations inanyofTREX1,RNASEH2A,RNASEH2B,
RNASEH2C, SAMHD1, ADAR or IFIH1. We report on 374
patients from 299 families with mutations in these seven genes.
Most patients conformed to one of two fairly stereotyped clinical
profiles; either exhibiting an in utero disease-onset (74 patients;
22.8% of all patients where data were available), or a post-natal
presentation, usually within the first year of life (223 patients;
68.6%), characterized by a sub-acute encephalopathy and a loss
ofpreviously acquired skills.Other clinicallydistinctphenotypes
were also observed; particularly, bilateral striatal necrosis (13
patients; 3.6%) and non-syndromic spastic paraparesis (12
patients; 3.4%). We recorded 69 deaths (19.3% of patients
with follow-up data). Of 285 patients for whom data were
available, 210 (73.7%) were profoundly disabled, with no usefulmotor, speech and intellectual function. Chilblains, glaucoma,
hypothyroidism, cardiomyopathy, intracerebral vasculitis, pe-
ripheral neuropathy, bowel inflammation and systemic lupus
erythematosus were seen frequently enough to be confirmed as
real associations with the Aicardi-Goutieres syndrome pheno-
type.Weobserved a robust relationship betweenmutations in all
seven genes with increased type I interferon activity in cerebro-
spinal fluid and serum, and the increased expression of interfer-
on-stimulated gene transcripts in peripheral blood.We recorded
a positive correlation between the level of cerebrospinal fluid
interferon activity assayed within one year of disease presenta-
tion and the degree of subsequent disability. Interferon-stimu-
lated gene transcripts remained high inmost patients, indicating
anongoingdisease process.On thebasis of substantialmorbidity
and mortality, our data highlight the urgent need to define
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300 AMERICAN JOURNAL OF MEDICAL GENETICS PART Acoherent treatment strategies for the phenotypes associatedwith
mutations in the Aicardi–Goutie`res syndrome-related genes.
Our findings also make it clear that a window of therapeutic
opportunity exists relevant to the majority of affected patients
and indicate that the assessment of type I interferon activity
might serve as a useful biomarker in future clinical trials.
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Aicardi–Goutie`res syndrome (AGS) is a rare genetic disorder most
consistently affecting thebrain and the skin. Thediagnosis is usually
made in the context of an early-onset encephalopathy characterized
by basal ganglia calcification and white matter abnormalities.
However, since the original description [Aicardi and Goutieres,
1984], a wider spectrum of disease presentation, progression and
outcome has been recognized. In 2007 [Rice et al., 2007b], we
reported a genotype-phenotype analysis of 98 caseswithpathogenic
variants in the fourgenes, TREX1 [Crowet al., 2006a],RNASEH2A,
RNASEH2B, and RNASEH2C [Crow et al., 2006b], known to be
associated with AGS at that time. Since then three further genes,
SAMHD1 [Rice et al., 2009], ADAR [Rice et al., 2012] and IFIH1
[Rice et al., 2014], have been described as mutated in patients
demonstrating a phenotype consistent with AGS, and the spectrum
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DOI 10.1002/ajmg.a.36887of disease resulting from mutations in the AGS-related genes has
broadened, in part due to the advent of the new sequencing
technologies.
These seven genes encode proteins, namely TREX1, the RNase
H2 complex, SAMHD1, ADAR and IFIH1 (MDA5), each of which
CROW ET AL. 301is involved in nucleic acidmetabolism/signaling. Patients withAGS
consistently demonstrate increased levels of interferon activity in
the cerebrospinal fluid and serum [Lebon et al., 1988], and an
increased expression of interferon-stimulated genes (ISGs) in
peripheral blood [Rice et al., 2013a], a so-called interferon signa-
ture. These observations are important in identifying AGS as an
inflammatory disorder associated with the induction of a type I
interferon mediated innate immune response, likely driven by
endogenously-derived nucleic acids [Crow and Rehwinkel, 2009].
Here we present genetic and clinical data on 374 mutation-
positive patients from 299 families encompassing all seven known
AGS-relatedgenes. Indoing so,weprovide a comprehensive viewof
the associated disease spectrum, natural history, and genotype-
phenotype correlations, information which is prerequisite for the
assessment of outcome in future clinical trials.FIG. 1. Numbers and percentages of families with Aicardi–
Goutie`res syndrome (AGS) with mutations in TREX1, RNASEH2A,
RNASEH2B, RNASEH2C, SAMHD1, ADAR and IFIH1. D: denotes
dominant mutation. One child with a neurological phenotype and
a single heterozygous mutation in TREX1, and three children
with single heterozygous mutations in RNASEH2B were also
identified. In addition, four families demonstrating autosomal
dominant segregation of familial chilblain lupus (FCL) with
mutations in either TREX1 (two families) or SAMHD1 (one
family) were ascertained. Mutations in RNASEH2B and TREX1
represent more than half of our cohort. Considering their
relatively recent identification, it is possible that the proportion
of patients with mutations in ADAR and IFIH1 may increase.MATERIALS AND METHODS
Patient data
Subjects were ascertained through our own clinical practice and
through contact with international collaborators. Patients were
included where we observed either biallelic mutations in one of
TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1 and
ADAR, a recognized heterozygous disease-causing mutation in
TREX1 (p.Asp18Asn, p.Asp18His or p.Asp200Asn) or ADAR (p.
Gly1007Arg), or a dominant mutation in IFIH1 (see Supplemen-
tary Table VII for cDNA mutations). We also collected data on
patients with a characteristic phenotype of AGS who were hetero-
zygous for otherwise presumed recessive mutations in these genes.
Variants were considered to be pathogenic on the basis of a
combination of criteria including multiple ascertainment in affect-
ed patients, appropriate segregation within families, de novo
occurrence, the output of pathogenicity prediction packages, evo-
lutionary conservation, frequency in publically available sequenc-
ing databases, and the results of published or previously
unpublished functional assays and structural studies. Mutations
are recorded according to Human Genome Variation Society
(HGVS) nomenclature and the following transcripts: TREX1,
NM_033629.4; RNASEH2A, NM_006397.2; RNASEH2B,
NM_024570.3; RNASEH2C, NM_032193.3; SAMHD1,
NM_015474.3; ADAR, NM_001111.4; IFIH1, NM_022168.2. A
multiplex ligation-dependent probe amplification (MLPA) assay
was used to look for copy number variants in TREX1, RNASEH2A,
RNASEH2B, RNASEH2C and SAMHD1 (MRC-Holland).
Clinical and laboratory data were obtained through direct
clinical contact and/or from medical records, recorded in a RED-
Capdatabase [Harris et al., 2009] and reviewed by either Y.J.C. (304
patients), S.O. (42 patients) or A.V. (28 patients). Information
about every clinical characteristic was not available for all patients.
Assessments of the gross motor function, manual ability and
communication status of patients over the age of 1 year were
made using the Gross Motor Function Classification System
(GMFCS) [Palisano et al., 1997], the Manual Ability Classification
System (MACS) [Eliasson et al., 2006] and the Communication
Function Classification System (CFCS) [Hidecker et al., 2011],
respectively.The study was approved by a U.K. Multicentre Research Ethics
Committee (reference number 04:MRE00/19), theMondino Ethics
Committee (3549/2009, September 30, 2009 and December 11,
2009) and the Children’s National Medical Center Institutional
Review Board.RESULTS
Mutation data
The mutations observed by gene, and the number of times (by
family) that they were seen, are given in Figure 1, Supplementary
Figure 1 (A–G) and Supplementary Tables I–VII.
Biallelic mutations were recorded in TREX1 (65 families: 22%),
RNASEH2A (14 families: 5%), RNASEH2B (104 families: 36%),
RNASEH2C (35 families: 12%), SAMHD1 (38 families: 13%) and
ADAR (18 families: 6%). Monoallelic, dominant, mutations of
IFIH1were identified in nine families.We ascertained four patients
with a neurological phenotype to have either a single p.Asp18Asn
(two patients), a p.Asp18His (one patient) or p.Asp200Asn (one
patient) mutation in TREX1, and five patients to harbor the
dominant p.Gly1007Argmutation inADAR. All of these dominant
302 AMERICAN JOURNAL OF MEDICAL GENETICS PART Amutations arose de novo, except in one family where an unaffected
father transmitted the ADAR p.Gly1007Arg mutation to two
daughters by two different partners. We identified three patients
with a combination of three predicted deleterious variants in two
genes (Supplementary Table VIII). Three families demonstrating
autosomal dominant segregation of an exclusively skin phenotype
termed familial chilblain lupus (FCL), with either a p.Asp18Asn
mutation in TREX1 (one family) or a p.Ile201Asn mutation in
SAMHD1 (one family), together with a single family segregating
FCL apparently due to a p.Gly126Trpfs*2mutation inTREX1 (plus
a p.Phe17Ser variant of uncertain significance) were also ascer-
tained. These FCL cases are not discussed further.
One of two recently described synonymous RNASEH2A var-
iants, c.69G>A (Val23Val) and c.75C>T (Arg25Arg), considered
to be pathogenic as a result of altered splicing, were identified in five
families [Rice et al., 2013b].We also recorded two intronic variants
in RNASEH2B (c.65–13G>A, three families; c.322–17A>G, one
family) which appear to affect mRNA splicing and are likely to be
disease causing (Supplementary Fig. 2, Supplementary Table III).
There were four children from four families with a convincing
clinical diagnosis of AGS in whom, after screening all seven AGS-
related genes, we could identify only a single, presumed recessive,
mutation (TREX1 p.Arg114His, one case; RNASEH2B p.Cys125-
Tyr, p.Leu52Trp and c.136þ1del, one case each)(Supplementary
Tables I, III). Thesemutations were present in an unaffected parent
in every family. In all other neurologically affected individuals we
were able to identify biallelic gene mutations (except relating to
patients with known dominant mutations of TREX1, ADAR and
IFIH1).Apart froma recurrent deletion (50 and including exon 1) of
SAMHD1 seen in 10 patients of Ashkenazi Jewish ancestry (Sup-
plementary Table V), we observed only one large deletion of
RNASEH2B (Supplementary Table III), and a single complex
deletion/duplication in SAMHD1 (Supplementary Table V).FIG. 2. Age at presentation by genotype. Percentage of patients with eit
the known AGS-related genes, in families where at least one individual h
Congenital infection-like describes patients with a neurological phenotyp
patients present within the first year of life. Mutations in TREX1 were mo
while children presenting after the age of one year were most likely to hDetails of recurrent mutations are given in Supplementary
Table IX. The p.Arg114His mutation in TREX1 was seen in 35 of
70 TREX1-related families. Although most were of northern Euro-
pean ancestry,we alsoobserved this variant in thehomozygous state
in a single family each of Turkish and Pakistani background. We
recorded a TREX1 p.Glu20Glyfs*82 mutation in eight families of
south Asian ethnicity (six in the homozygous state). As previously
described [Crow et al., 2003; Crow et al., 2006a], a founder
mutation, p.Arg164*, in TREX1 segregates in patients from the
Cree Indian population. Remarkably, in a pan-ethnic cohort of 107
families with mutations in RNASEH2B, 97 harbored the p.
Ala177Thr substitution (48 homozygotes; 49 heterozygotes).
Twenty-four families of south Asian origin were homozygous
for a p.Arg69Trp mutation in RNASEH2C, likely indicative of a
founder mutation. As stated above, we recorded a recurrent dele-
tion of SAMHD1 in 10Ashkenazim families. A p.Arg145*mutation
in SAMHD1, occurring on a shared ancestral haplotype, was seen in
five families, four of whom were known to be Maltese. A p.
Pro193Ala mutation was seen, always in the heterozygous state,
in 13 of 22 ADAR mutation-positive families, mainly of northern
European descent.Clinical data
Thirty-seven patients (11.4%) (25 TREX1; two RNASEH2A; one
RNASEH2B; three RNASEH2C; three SAMHD1; one ADAR; two
IFIH1) presented at birthwith a congenital infection-like syndrome
comprising abnormal neurological signs (e.g., poor feeding, irrita-
bility, abnormal tone, abnormal movements and seizures) with
thrombocytopenia and hepatosplenomegaly, thus indicating a
prenatal onset of disease (Fig. 2). A further 37 patients (11.4%)
(13 TREX1; one RNASEH2A; nine RNASEH2B; seven RNASEH2C;
six SAMHD1; one ADAR) demonstrated neurological features ather biallelic mutations or a recognized dominant mutation in one of
as a neurological phenotype, i.e., excluding families with only FCL.
e at birth plus thrombocytopenia and hepatosplenomegaly. Most
st frequently associated with a congenital infection-like presentation,
arbor mutations in ADAR or IFIH1.
FIG. 3. Development prior to presentation according to mutated gene. Percentage of patients with either biallelic mutations or a recognized
dominant mutation in one of the known AGS genes, in families where at least one individual has a neurological phenotype, i.e., excluding
families only with FCL. Never normal: presentation at or after birth without a period of normal development. Uncertain: presentation after birth
where developmental status prior to presentation was uncertain. Normal: presentation after birth with definitely normal development prior to
disease onset. Patients presenting with a period of normal development were more likely to harbor mutations in ADAR or IFIH1.
CROW ET AL. 303birth in the absenceofobvious systemic features.Althoughprecisely
dating the onset of disease was difficult in most cases presenting
beyond the neonatal period, the majority (223 of 325; 68.6%) of
patients experienced obvious neurological dysfunction within the
first year of life (Fig. 2). In those cases where the clinical history was
unequivocal, 65 children (18.0%) demonstrated normal develop-
ment up until the time of the onset of symptoms (Fig. 3), with the
likelihood of exhibiting normal development prior to presentation
being 63%, 57% and 21% in relation to mutations in IFIH1,ADAR
and RNASEH2B, respectively, Twenty-eight patients (8.6%) pre-
sented after the age of 1 year, with 35% and 30% of patients with
mutations in ADAR and IFIH1, respectively, demonstrating the
onset of disease after this age. The latest age at presentation known
to us was a child with a p.Gly1007Arg mutation in ADAR who
developed features of a subacute dystonia beginning at age 5.
Most patients were considered to conform to the relatively
stereotyped clinical profile previously described in the context of
AGS, characterized by severe neurological dysfunction at birth or
with onset in the first year of life, variably manifesting as spasticity,
dystonia, seizures (140 of 362 patients, 39%), cortical blindness
(111 of 362 patients, 31%) sometimes with pale optic discs,
progressive microcephaly and psychomotor retardation. However,
we also observed 13 children (3.6%) with the acute or sub-acute
onset of severe dystonia and features of bilateral striatal necrosis on
neuroimaging, in the absence of other features of AGS, all of whom
carried mutations in ADAR (Supplementary Table X [Livingston
et al., 2014]). Furthermore, we identified 12 patients (3.4%) (six
RNASEH2B; three SAMHD1; two ADAR; one IFIH1) with a pure
spastic paraparesis phenotype in the presence of normal neuroim-
aging, or non-specific changes in cerebral white matter, and pre-
served intellect [Crow et al., 2014b].An assessment of gross motor function, manual ability and
communication status at last contact was made in a total of 294,
291, and 285 patients, respectively (Supplementary Figs. 3–5). Of
the latter, 210 (74%) patients were recorded to have none of any
purposeful gross motor, hand and communication function. Only
14 of 294 patients (four RNASEH2B; one RNASEH2C; four
SAMHD1; two ADAR; three IFHI1) were able to walk with no/
minimal support. Patients with mutations in RNASEH2B,
SAMHD1,ADAR and IFIH1weremore likely to retain some useful,
albeit often still limited, motor and communication abilities, i.e.,
they scored better than V, V and V on the GMFCS, MACS, and
CFCS rating scales (threeTREX1; twoRNASEH2A; 32RNASEH2B;
three RNASEH2C; 19 SAMHD1; 10 ADAR; six IFIH1) (Fig. 4). A
marked discrepancy in the severity of neurological outcome was
observed between siblings in a small number of families. For
example, an older sister to a severely neurologically affected female
child was identified to have a homozygous p.Arg69Trpmutation in
RNASEH2C and a history of chilblains in the absence of any other
features [Vogt et al., 2013].
We recorded data relating to status at last contact/known age at
death in 357 patients (Fig. 5, Supplementary Table XI). Sixty-nine
cases (19.3%)were ascertained to have died, with 37 of these deaths
occurring in the first 5 years after birth, and mutations in TREX1
being associatedwith the highest number of deaths (26; 33.3%of all
patients with mutations in TREX1). Sixty-eight patients (19.0%)
were known to have lived beyond the age of 15 years, and we are
aware of eight patients still alive at more than 30 years of age.
Chilblains [Tolmie et al., 1995] were reported in 113 patients
(31.2%) and were seen in association with mutations in all of the
AGS-related genes, although only one patient with ADAR-related
disease was reported to exhibit such lesions (in contrast to 26 of 48
FIG. 4. Degree of disability by mutated gene. Numbers represent the sum of GMFCS (Gross Motor Function Classification System for Cerebral
Palsy), MACS (Manual Ability Classification System), and CFCS (Communication Function Classification System) score at time of last contact/
death for each patient where three is normal and 15 is profoundly disabled. Number of patients with either biallelic mutations or a recognized
dominant mutation in one of the known AGS-related genes, in families where at least one individual has a neurological phenotype, i.e.,
excluding families with only FCL. Although most patients (74%) are severely neurologically damaged, this was more likely to be the case in
children with mutations in TREX1, RNASEH2A or RNASEH2C.
304 AMERICAN JOURNAL OF MEDICAL GENETICS PART A[54.2%] patients withmutations in SAMHD1) (Fig. 6, Supplemen-
tary Table XII). The nextmost frequently described association was
with glaucoma [Crow et al., 2004], which was recorded in 23
patients (6.3%) (10 of 48 [20.8%] patients with SAMHD1 muta-
tions; no patients withmutations inADAR or IFIH1).Most cases of
glaucomapresented in the first 6months of life, but one patient was
diagnosed with bilateral disease requiring treatment at the age of
6 years. Intracerebral large vessel disease [Ramesh et al., 2010],
usually identified retrospectively after a catastrophic intracerebral
accident, was confirmed in nine patients, all with mutations in
SAMHD1. A patient with mutations in TREX1 suffered a life-
threatening intracerebral hemorrhage at age of 3 years, but without
prior imaging evidence of a vascular anomaly. A further patient
with TREX1 mutations [Olivieri et al., 2013] was noted to have a
porencephalic lesion at the level of the left caudate nucleus due to an
ischemic event in the territory of the perforating vessels.
Hypothyroidism requiring replacement therapy was reported in
14 patients (3.9%) (six TREX1). Twelve cases (3.3%), nine with
mutations in TREX1, were diagnosed with an infantile-onset
hypertrophic cardiomyopathy. Eight patients were recorded to
have a demyelinating peripheral neuropathy. Four patients were
diagnosed with central diabetes insipidus (three TREX1), one with
diabetes mellitus, one with hyperparathyroidism, one with growth
hormone deficiency and one with both autoimmune gastritis and
adrenal insufficiency. Six patients experienced inflammatory gas-
trointestinal problems (variably diagnosed as Crohn disease, atro-
phic gastritis, coeliac disease, autoimmune hepatitis and non-
specific colitis). Four patients (two ADAR; two IFIH1) received a
formal diagnosis of systemic lupus erythematosus (SLE), and one
(TREX1) case developed antiphospholipid syndrome [Olivieriet al., 2013]. Three patients (two SAMHD1; one TREX1) demon-
strated a panniculitis which in one case necessitated the use of high-
dose immunosuppressive therapy. As previously described [Abe
et al., 2014; Rice et al., 2007a], particularly widespread involvement
of the skin was seen in three patients with an AGS phenotype due to
dominant mutations in TREX1, with one of these patients
experiencing a severe dactylitis showing limited responsive to
high-dose immunosuppression. Two patients with SAMHD1-re-
lated disease developed a significant non-destructive arthropathy
[Dale et al., 2010]. One affected individual with a homozygous
splice-site mutation (c.1609–1G>C) in SAMHD1, and an addi-
tional predicted pathogenic heterozygous lesion in ADAR (p.
Ala562Thr), developed chronic lymphocytic leukemia at the age
of 24 years [Clifford et al., 2014].Cerebrospinal fluid (CSF) and serum interferon
activity, interferon-stimulated gene transcripts
(ISGs) in blood, and CSF pterin levels
We have recently provided a detailed assessment of the level of
interferon activity in CSF and serum measured using a cytopathic
cell assay [Lebon et al., 1988; Lebon et al., 2002], and of the
expression of a panel of ISGs in peripheral blood assessed by
quantitative PCR [Rice et al., 2013a]. Summarizing data across
the complete cohort described here, interferon activity in CSF and
serum was consistently raised in mutation-positive patients, was
negatively correlated with age (CSF, r¼0601; serum, r¼
0274), and was higher in CSF than in serum in 93 of 134 paired
samples (Supplementary Figs. 6–8, Supplementary Table XIII).
FIG. 5. (A) Known status of AGS patients by age at last contact/age at death. (B) Known status of AGS patients by mutated gene. Number of
patients with either biallelic mutations or a recognized dominant mutation in one of the known AGS-related genes, in families where at least
one individual has a neurological phenotype i.e., excluding families with FCL only. Although there is a significant mortality associated with
mutations in the AGS-related genes, a number of patients have been recorded to survive into adulthood. Mutations in TREX1 were associated
with a greater risk of death than mutations in the other AGS-related genes.
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FIG. 6. Frequency of associated phenotypes in AGS patients.
Number of patients with either biallelic mutations or a
recognized dominant mutation in one of the known AGS-related
genes, in families where at least one individual has a neurologi-
cal phenotype, i.e., excluding families with FCL only. SLE/APLS:
Systemic lupus erythematosus/antiphospholipid syndrome. In-
flammatory gastrointestinal disease: Crohns disease, atrophic
gastritis, coeliac disease, autoimmune hepatitis, non-specific
colitis. Other autoimmune: one diabetes mellitus, one hyperpara-
thyroidism, one growth hormone deficiency, one adrenal
insufficiency.
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pterin) in CSF to be elevated in 48 patients sampled on 43 of 52
occasions, and to be negatively correlated with age (r¼0.617)
(Supplementary Fig. 9, Supplementary TableXIII).We collated 233
CSFwhite cell count readings (from 158 patients: 167 of 233 results
abnormal) (Supplementary Table XIII), which were also negatively
correlated with age (r¼0.5559) (Supplementary Fig. 10). We
derived an interferon score in peripheral blood for 100 patients
measured on 146 occasions. Apositive score (>2.4)was recorded in
67 of 68 (98%) patients with mutations in any of TREX1, RNA-
SEH2A, RNASEH2C, SAMHD1, ADAR and IFIH1. In contrast, 10
of 32 (31%) patients withmutations inRNASEH2Bdemonstrated a
normal interferon score (<2.4, i.e., within þ2 SD of the control
population) (Fig. 7, Supplementary Fig. 11, Supplementary
Table XIII). While 77% (160 of 207) and 73% (115 of 158) of,
respectively, CSF and serum interferon activitymeasurements were
made before the age 24 months, only 15 of 146 (10%) ISG readings
were made before this age (with the majority, 80% — 118 of 146,
taken after the age of 4 years). The median value of CSF interferon
activity recorded within 1 year of disease onset was significantly
lower in patients with a combined score across the GMFCS, MACS
and CFCS rating scales of <15, and demonstrated a positive
correlation with disability in patients with mutations in all genes
(Fig. 8).DISCUSSION
Here, we present the mutational and phenotypic spectrum across
seven genes known to be associatedwith a clinical diagnosis of AGS.Several points of note arise from these molecular and clinical data,
which we discuss below.
Firstly, homozygous or compound heterozygous null mutations
in TREX1 and in SAMHD1 are seen frequently, consistent with a
complete loss of protein activity. In contrast, we have never
observed biallelic null mutations in any of RNASEH2A, RNA-
SEH2B, RNASEH2C or ADAR, indicating that such a state is either
incompatible with life or is associated with phenotypes not ascer-
tainedhere.We identifiedone child tohave amaternally inheritedC
terminus frameshift mutation (p.Leu287Cysfs*11) in TREX1 (in
combination with a second mutation), a molecular lesion previ-
ously considered to be exclusively relevant to the clinically distinct
disorder retinal vasculopathy with cerebral leukodystrophy
(RVCL) [Richards et al., 2007]. Whether the child and his mother
are at risk of developing RVCL is unclear, but this result indicates
that such mutations can be associated with the AGS phenotype.
Although AGS is most frequently inherited as an autosomal
recessive trait, mutations in IFIH1 are all heterozygous gain-of-
function [Rice et al., 2014], while the p.Gly1007Arg mutation in
ADAR, seen in five patients, as well as the p.Asp18Asn, p.Asp18His
and p.Asp200Asn mutations in TREX1, likely act as heterozygous
dominant-negative alleles. To our knowledge, dominantmutations
associated with a neurological phenotype have not been conclu-
sively documented in RNASEH2A, RNASEH2B, RNASEH2C or
SAMHD1.
Except in those patients with a previously recognized domi-
nant mutation, we were able to define two likely pathogenic
variants in all but four patients. These data indicate that patho-
genic variants in non-coding regions relevant to gene regulation
are rare in the clinical context that we have ascertained. Whether
or not these four variants are contributory to the phenotype, or
represent a chance association, is unclear. Possibilities include the
presence of a cryptic second mutation, or non-penetrance in the
transmitting parent. The significance of our finding of three
patients with a combination of three predicted deleterious muta-
tions in two genes is also uncertain. In this regard, we note that
very few patients have been sequenced for mutations in all seven
AGS-related genes.
We observed several founder mutations which may aid in
screening of discrete populations, most obviously in the Ashkenaz-
imwhere a carrier frequency of 1/138was recorded for the recurrent
SAMHD1 deletion (http://www.ashg.org/2013meeting/abstracts/
fulltext/f130121959.htm). We also note that the p.Pro193Ala mu-
tation in ADAR and the p.Ala177Thr substitution in RNASEH2B
are associated with a non-negligible carrier frequency in the general
population. In particular, the p.Pro193Ala has been seen on 32 and
nine alleles in 4300 European Americans and 2203 African Amer-
icans, respectively (http://evs.gs.washington.edu/EVS/).
Although it was difficult to precisely date the onset of disease in
many cases, in 65 patients, it was clear that the affected child
demonstrated an initial period of normal development, with 28
children presenting after the age of 1 year. How the AGS-associated
disease process is induced is uncertain, but could relate to an
environmental trigger or genetic background. At least in the case
of the ADAR-associated bilateral striatal necrosis phenotype, sev-
eral parents gave a clear history of the onset of disease shortly after
an infectious episode [Livingston et al., 2014].
FIG. 7. (A) Quantitative reverse transcription PCR (qPCR) showing the interferon score derived from a panel of six interferon stimulated genes
(ISGs) measured in whole blood in 100 AGS patients and 29 controls. The median fold change of the six probes combined was calculated to
given an interferon score for each individual. Red bars show the median RQ value for each probe in each group. Samples colored red have a
positive interferon score (>2.4) whereas samples colored blue have a normal interferon score (within þ2 SD of the median for the control
population). For subjects with repeat samples, the median combined measurement is shown. RQ is equal to 2DDCt, i.e., the normalized fold
change relative to a control. One way ANOVA with Dunnett’s multiple comparison test. Almost all patients demonstrate a positive interferon
score compared to controls, except for individuals with mutations in RNASEH2B, where 31% of patients demonstrated a normal interferon
signature. (B) ISG RQ by mutated gene compared to controls. Red bars show the median RQ value for each probe in each group. One way
ANOVA with Dunnett’s multiple comparison test. These data sets include some measurements published previously [Rice et al., 2013a]. These
data indicate a clear upregulation of the expression of the six interferon stimulated genes assayed in patients compared to controls, with
lower median values in patients with mutations in RNASEH2B.
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FIG. 8. CSF interferon measurements in patients assayed within one year of disease onset, plotted against disability score. (A) CSF interferon
measurements in patients with a combined GMCSF, MACS, and CFCS score of 15 compared to patients with a score less than 15. Red bars
show the median CSF interferon. Unpaired t-test of log transformed data. (B) CSF interferon measurements plotted against the combined
disability score. In patients with serial measurements only the first measurement is shown. These data sets include some measurements
published previously [Lebon et al., 1988, Lebon et al., 2002, Rice et al., 2013a]. There is a possible association between interferon activity
in the cerebrospinal fluid measured in the first year of life and disability outcome.
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CROW ET AL. 309The non-prospective nature of our data collection, with incom-
plete follow-up information and probable under-ascertainment of
certain disease features, means that we are not able to derive formal
mortality rates or risk statistics. However, it is clear fromour results
that AGS is a severe disease, with 74% of our cohort left with a
profound combined deficit of motor and communication activity
(we note that the CFCS does not assess intellectual function, and
that some patients retained useful intellectual ability in the face of a
major disturbance of communication skills). Mutations in TREX1
were frequently associated with a neonatal presentation, implying
an in utero onset of disease, and with a high number of deaths.
Mutations in ADAR, and IFIH1 were more likely to be seen in
patients presenting after a definite period of normal development,
and in patients presenting after the age of 1 year. Patients with
mutations in these same two genes, as well as in RNASEH2B and
SAMHD1, could also demonstrate some preservation of manual
ability and communication skills. As well as clinically important
differences in outcome between genes, we observed the same
mutations in association with clinically distinct phenotypes (for
example, mutations in ADAR can cause ‘classical’ AGS, ‘uncom-
plicated’ spastic paraparesis and bilateral striatal necrosis). There is
no definite explanation for this variability in phenotypic expression
and clinical severity, ranging from complete non-penetrance (in-
cluding two IFIH1mutation-positive individuals demonstrating a
robust and sustained interferon signature who remain clinically
asymptomatic at the ages of 48 and 79 years) [Rice et al., 2014],
through isolated skin disease, to a severe neurological phenotype.
Such variation, albeit apparently rare [Vogt et al., 2013], must be
taken into accountwhen interpreting the outcome of future clinical
trials.
As recently described, our data show an almost 100% correlation
between a positive interferon score and the presence of disease-
associated mutations in TREX1, RNASEH2A, RNASEH2C,
SAMHD1, ADAR, and IFIH1 [Rice et al., 2013a]. In contrast,
31%of patientswithmutations inRNASEH2Bdidnot demonstrate
an overexpression of ISG transcripts in blood. Since ISG sampling
was usually performedmany years after initial diagnosis, it remains
possible that all patients demonstrate apositive interferon signature
at the time of disease onset, and that levels fall more quickly in
patients with RNASEH2B mutations. Of note, our data suggest a
positive correlation between the levels of CSF interferon activity
assayed within one year of disease presentation, and disability as
measured using a combined score across the GMFCS, MACS, and
CFCS rating scales.
Beyond an initial encephalopathic phase, generally lasting
several months, continued neurological deterioration was not
obvious in most patients; indeed, some parents reported a slow
but steady acquisition of new skills over time (although we also
note that it is difficult to assess a loss/gain of skills in a child who
is already profoundly neurologically compromised, and that a
few parents described possible further episodes of regression).
This observation is consistent with the survival of some patients
into the fourth decade of life, and a definite trend towards a
decline in interferon activity in CSF and serum, as well as CSF
levels of the inflammatory marker neopterin [Dale et al., 2009]
and the CSF white cell count, over time. Since only a limited
number of samples were collected during the early stage of thedisease, our ISG data do not contradict this suggestion, although
they clearly demonstrate that an interferon signature persists long
term in most patients, indicative of an ongoing inflammatory
process. Such persistence is reflected clinically by the high
frequency of recurrent chilblains, most typically occurring in
the winter months, and the intracranial large-vessel disease
particularly seen in patients with mutations in SAMHD1. Why
the AGS-associated clinical phenotype apparently ‘abates’ neu-
rologically beyond the initial subacute encephalopathic phase,
and whether or not patients are at risk of neurological disease
progression, or ‘flares’, in later life, is still uncertain.
We note the consistent association of the AGS phenotype with
glaucoma, hypothyroidism, cardiomyopathy and a demyelinating
peripheral neuropathy. All might be overlooked in the case of a
severely disabled individual unable to report symptoms, and so we
would recommend that these states are searched for on a proactive
basis. Empirically, and because of the possibility for treatment, we
would suggest life-long surveillance, perhaps annually, for glaucoma
and thyroid function. Our ownwork [Ramesh et al., 2010], and that
of others [Thiele et al., 2010; Xin et al., 2011], shows that the risk of
cerebrovascular accidents in the context ofSAMHD1-relateddisease
is high, and indicates a particular role for SAMHD1 in blood vessel
integrity and homeostasis. Given the potential for intervention,
individuals with mutations in SAMHD1might benefit from screen-
ing for intracranial arteriopathy, although such a decision would
need to take account of the overall clinical situation and continued
uncertainty about management in the face of such lesions.
PatientswithbothAGSandSLEwerefirst describedover 14years
ago [Aicardi and Goutieres, 2000; Dale et al., 2000], and heterozy-
gous mutations in TREX1 have been identified in non-syndromic
lupus [Lee-Kirsch et al., 2007]. However, the frequency with which
such mutations occur in SLE is unclear [Barizzone et al., 2013;
Namjou et al., 2011]. Althoughwehavenot undertakenprospective
testing of a large group of patients specifically addressing the point,
our data indicate that the frequency of clinically diagnosed lupus in
patients with AGS is low (only four cases in our series). More
generally, following our description of progressive arthropathy
with distal joint contractures and painful mouth ulcers in associa-
tion with biallelic SAMHD1 mutations [Dale et al., 2010], and
considering the associated high frequency of chilblains (54%),
glaucoma (21%) and intracranial vasculopathy (18%), we would
suggest that there is a need to consider mutation analysis of
SAMHD1 (and possibly the other AGS-related genes), in a broad
range of inflammatory phenotypes.
Our experience indicates that carriers of recessive mutations in
TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1 and
ADAR do not normally manifest disease features. In particular,
we are not aware of a proven increase in the incidence of cancer in
these individuals, nor of cancer in affected patients. However, the
documented role of the RNase H2 complex in removing mis-
incorporated ribonucleotides from DNA [Reijns et al., 2012],
and the observation of a patient with mutations in SAMHD1
developing chronic lymphocytic leukemia at the age of 24 years
[Clifford et al., 2014], indicates the need for long-term observation
of patients for features of malignancy.
We would not expect to be able to reverse neurological damage
already accrued at the time of initiating treatment, a fact of
310 AMERICAN JOURNAL OF MEDICAL GENETICS PART Aparticular relevance for patients affected in utero and displaying
pathological signs at birth. However, the majority of children with
AGSdemonstrate theonset of disease at a variable timepost-natally.
This observation is important in suggesting that treatment in the
early stages of the disease might result in an attenuation of the
associated inflammation and consequent tissue injury. In certain
cases, e.g., where chilblains are a particular problem, and in the
context of the recognized later-presenting phenotypes described
above, treatment beyond the sub-acute encephalopathic phase
might be beneficial even in the presence of significant neurological
dysfunction.
With the integration of new sequencing technologies into stan-
dard clinical practice, we predict that the spectrum of phenotypes
associated with mutations in the AGS-related genes will broaden.
These observations beg the question as towhether such cases should
actually be referred to as AGS. Irrespective of nosology, it is
probable that these phenotypes likely all relate to a common
pathology, involving an upregulation of type I interferons stimu-
lated by endogenous nucleic acids [Crow, 2011; Crow, 2015], and
might therefore potentially benefit from similar anti-interferon/
anti-inflammatory therapeutic strategies [Crow et al., 2014a].
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